natgillin/translations-raw huggingface dataset:
Klinisk effekt og sikkerhed hos mænd
Clinical efficacy and safety in men
Klinisk effekt TDM4370g/BO21977
Clinical efficacy TDM4370g/BO21977
Klinisk effekt ved behandling af Pagets sygdom af knoglerne
Clinical efficacy in the treatment of Paget’s disease of the bone
Klinisk effekt ved osteoporose i forbindelse med længerevarende systemisk glukokortikoidbehandling Effekten og sikkerheden af zoledronsyre ved behandling og forebyggelse af osteoporose i forbindelse med længerevarende systemisk glukokortikoidbehandling blev vurderet i et randomiseret, multicenter, dobbeltblindet, stratificeret, aktivt kontrolleret studie med 833 mænd og kvinder i alderen 18-85 år (gennemsnitsalder for mænd 56,4 år; for kvinder 53,5 år) behandlet med > 7,5 mg prednisolon (eller tilsvarende) oralt dagligt.
The efficacy and safety of zoledronic acid in the treatment and prevention of osteoporosis associated with long-term systemic glucocorticoid therapy were assessed in a randomised, multicentre, double-blind, stratified, active-controlled study of 833 men and women aged 18-85 years (mean age for men 56.4 years; for women 53.5 years) treated with > 7.5 mg/day oral prednisone (or equivalent).
Klinisk erfaring med akut overdosis af Zoledronsyre Teva er begrænset.
Clinical experience with acute overdose of zoledronic acid is limited.
Klinisk erfaring med epoetiner peger på, at risikoen for hypertension og trombose kan nedbringes ved at titrere dosis for at opretholde et hæmoglobinniveau på mellem 10 til 12 g/dl.
Clinical experience with epoetins suggest hypertension and thrombosis risk may be reduced by titrating the dose to maintain haemoglobin levels between 10 to 12 g/dl.
Klinisk erfaring med immunglobuliner indikerer, at der ikke er skadelige virkninger på fertilitet.
Clinical experience with immunoglobulins suggests that no harmful effects on fertility are to be expected.
Klinisk erfaring med MabThera koncentrat til opløsning til infusion ved non-Hodgkin-lymfom
Clinical experience of MabThera concentrate for solution for infusion in Non-Hodgkin’s lymphoma
Klinisk erfaring med MabThera subkutan formulering til kronisk lymfatisk leukæmi
Clinical experience of MabThera subcutaneous formulation in chronic lymphocytic leukaemia
Klinisk erfaring med MabThera subkutan formulering til non-Hodgkin-lymfom
Clinical experience of MabThera subcutaneous formulation in Non-Hodgkin’s lymphoma
Klinisk erfaring med MabThera subkutan formulering til non-Hodgkin-lymfom er baseret på data fra et fase III-klinisk studie (SABRINA BO22334) med patienter med follikulært lymfom (FL) og et fase Ib-dosisfastsættelses-/dosisbekræftende studie (SparkThera BP22333) med patienter med FL.
The clinical experience of MabThera subcutaneous formulation in Non-Hodgkin’s lymphoma is based on data from a phase III clinical trial (SABRINA BO22334) in patients with follicular lymphoma (FL) and a phase Ib dose-finding/dose-confirmation trial (SparkThera BP22333) in patients with FL.
Klinisk erfaring med samtidig administration af bosentan og warfarin hos patienter med pulmonal arteriel hypertension medførte ingen klinisk relevante ændringer i International Normalized Ratio (INR) eller warfarindosis (initialværdi versus afslutning på de kliniske undersøgelser).
Clinical experience with concomitant administration of bosentan with warfarin in patients with pulmonary arterial hypertension did not result in clinically relevant changes in International Normalized Ratio (INR) or warfarin dose (baseline versus end of the clinical studies).
Klinisk erfaring ved granulomatose med polyangiitis (Wegeners granulomatose) og mikroskopisk polyangiitis.
Clinical experience in granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis
Klinisk erfaring ved non-Hodgkin-lymfom og kronisk lymfatisk leukæmi
Clinical experience in Non-Hodgkin’s lymphoma and in chronic lymphocytic leukaemia
Klinisk evaluerbar
Clinically evaluable
Klinisk forbedring med Reconcile forventes inden for 1 eller 2 uger.
Clinical improvement with Reconcile is expected within 1 or 2 weeks.
Klinisk forbedring målt ved sPGA-, PASI-50- og PASI-90- respons blev også vist efter uge 16.
Clinical improvement measured by sPGA, PASI-50 and PASI-90 responses were also demonstrated at Week 16.
Klinisk forværrende hændelser
Clinical Worsening Events
Klinisk har følgende stoffer vist sig at øge blodkoncentrationer af tacrolimus:
Clinically, the following substances have been shown to increase tacrolimus blood levels:
Klinisk helbredelse, mITT-population
Clinical Cure, mITT Population
Klinisk håndtering
Clinical Management:
Klinisk hæmatologi og levertal bør monitoreres regelmæssigt igennem hele behandlingen med eltrombopag, og eltrombopagdosis skal justeres på basis af trombocyttallet som vist i tabel 3.
Clinical haematology and liver tests should be monitored regularly throughout therapy with eltrombopag and the dosage regimen of eltrombopag modified based on platelet counts as outlined in Table 3.
Klinisk hæmatologi og levertal skal monitoreres regelmæssigt igennem hele behandlingen med eltrombopag, og eltrombopagdosis skal justeres på basis af trombocyttallet som vist i tabel 3.
Clinical haematology and liver tests should be monitored regularly throughout therapy with eltrombopag and the dosage regimen of eltrombopag modified based on platelet counts as outlined in Table 3.
Klinisk information kommer hovedsagelig fra et prospektivt forsøg (n= 24 patienter) hos børn og unge, som ved diagnose var i alderen fra 5 måneder til 16 år (aldersmedian: 4 år), der havde en ikke- resektérbar primærtumor, eller som udviste et tumor tilbagefald eller en metastatisk sygdom; de fleste af børnene (75 %) fremstod med endokrine symptomer.
Clinical information comes mainly from a prospective trial (n= 24 patients) in children and adolescents aged at diagnosis from 5 months to 16 years (median age: 4 years) who had an unresectable primary tumour or who presented a tumour recurrence or a metastasic disease; most of the children (75%) presented with endocrine symptoms.
Klinisk kemi
Clinical chemistry
Klinisk kommentar
(0.92-1.02)
Klinisk kommentar
exposure of fexofenadine.
Klinisk kommentar
exposure of ranitidine.
Klinisk kommentar
OATP1B
Klinisk komplet respons (CCR) %
Clinical Complete Response (CCR)
Klinisk kontrol anbefales dog, da der kan opstå
However, clinical monitoring is recommended
Klinisk monitering anbefales ved
Clinical monitoring is
Klinisk monitorering
monitoring is recommended.
klinisk monitorering (ekg
as co-administration may
Klinisk monitorering af den terapeutiske effekt og bivirkninger
Clinical monitoring of therapeutic effect and adverse events is
Klinisk monitorering af terapeutiske
Clinical monitoring of therapeutic
Klinisk monitorering anbefales ved
Clinical monitoring is
Klinisk monitorering anbefales ved co-administration af boostet PREZISTA med kortikosteroider.
Clinical monitoring is recommended when co-administering boosted PREZISTA with corticosteroids.
Klinisk monitorering anbefales ved co-administration af PREZISTA med lavdosis ritonavir og kortikosteroider.
Clinical monitoring is recommended when co-administering PREZISTA with low dose ritonavir with corticosteroids.
klinisk monitorering anbefales.
monitoring is recommended.
klinisk monitorering bør
and/or clinical monitoring
Klinisk monitorering for
Nevirapine
Klinisk monitorering kan være nødvendig ved samtidig administration med EVOTAZ.
Clinical monitoring may be needed upon co- administration with EVOTAZ.
Klinisk monitorering og
Clinical monitoring and
Klinisk monitorering og dosisjustering kan være nødvendig for s- mephenytoin.
Clinical monitoring and dose adjustment maybe needed for s-mephenytoin.
klinisk monitorering og passende
etting, which ensures close clinical
klinisk monitorering og passende
monitoring and appropriate medical
Klinisk nytteværdi (ORR+MR) [n (%)]
Clinical Benefit Rate (ORR+MR) [n(%)]
Klinisk og biologisk overvågning når antithrombin anvendes sammen med heparin, lavmolekylært heparin eller andre koagulationshæmmere, der forstærker antithrombins koagulationshæmmende virkning:
Clinical and biological surveillance when antithrombin is used together with heparin, low molecular weight heparin or other anticoagulants which potentiate the anticoagulant activity of antithrombin:
Klinisk overvågning af terapeutisk effekt og bivirkninger anbefales, når disse lægemidler administreres samtidig med Kaletra.
Clinical monitoring of antiviral efficacy is recommended when these medicines are concomitantly administered with Kaletra.
Klinisk overvågning af terapeutisk virkning og bivirkninger anbefales.
Clinical monitoring of therapeutic effect and adverse reactions is recommended.
Klinisk overvågning anbefales imidlertid, da det kan være nødvendigt at justere vedligeholdelsesbehandlingen med methadon hos nogle patienter.
However, clinical monitoring is recommended as methadone maintenance therapy may need to be adjusted in some patients.
Klinisk overvågning anbefales når dabigatran administreres samtidigt med P-gp-hæmmere.
Clinical monitoring is recommended when dabigatran is co-administered with P-gp inhibitors.
Klinisk overvågning anbefales og en øget dosis af olanzapin kan overvejes, hvis nødvendigt (se pkt.
Clinical monitoring is recommended and an increase of olanzapine dose may be considered if necessary (see section 4.5)
Klinisk overvågning anbefales og når dabigatran administreres samtidigt med P-gp-hæmmere.
Clinical monitoring is recommended when dabigatran is co-administered with P-gp inhibitors.
Klinisk overvågning og
Clinical monitoring and
klinisk praksis.
practice
klinisk praksis.
practice.
Klinisk relevant bradykardi
Clinically relevant bradycardia
klinisk relevant bradykardi (vedvarende hjertefrekvens < 50 slag i minuttet)
clinically relevant bradycardia (persistent heart rate < 50 bpm);
Klinisk relevant forbedring var på forhånd defineret som mindst en 4- pointsforbedring på ADAS-Cog, ingen forværring på ADCS-CGIC og ingen forværring på ADCS- ADL.
Clinically relevant improvement was defined a priori as at least 4-point improvement on the ADAS-Cog, no worsening on the ADCS-CGIC, and no worsening on the ADCS-ADL.
klinisk relevant hjerteinsufficiens med nedsat ejektionsfraktion fra venstre ventrikel
clinically relevant heart failure with reduced left-ventricular ejection fraction
Klinisk relevant hjertesvigt med nedsat uddrivningsfraktion fra venstre ventrikel
Clinically relevant heart failure with reduced left-ventricular ejection fraction
Klinisk relevant mindre blødning
Clinically relevant non-major
Klinisk relevant reduktion i HbA1c sammenlignet med kontrol blev observeret uanset baggrundsbehandling ved baseline.
Clinically meaningful reductions in HbA1c compared to control were also observed with 25 mg alogliptin regardless of baseline background treatment.
Klinisk relevant toksicitet, som blev rapporteret hos ≥ 1 % og ≤ 5 % af de patienter, der var randomiseret til cisplatin og pemetrexed, omfattede: forhøjet AST, forhøjet ALT, infektion, febril neutropeni, nyresvigt, pyreksi, dehydrering, konjunktivitis og nedsat kreatinin-clearance.
Clinically relevant toxicity that was reported in ≥ 1% and ≤ 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: AST increase, ALT increase, infection, febrile neutropenia, renal failure, pyrexia, dehydration, conjunctivitis, and creatinine clearance decrease.
Klinisk relevant toksicitet, som blev rapporteret hos ≥ 1 % og ≤ 5 % af de patienter, der var randomiseret til cisplatin og pemetrexed, omfattede: forhøjet AST, forhøjet ALT, infektion, febril neutropeni, nyresvigt, pyreksi, dehydrering, konjunktivitis og nedsat kreatinin-clearance.
Clinically relevant toxicity that was reported in ≥ 1% and ≤ 5% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: AST increase, ALT increase, infection, febrile neutropenia, renal failure, pyrexia, dehydration, conjunctivitis, and creatinine clearance decrease.
klinisk relevant.
relevant.
Klinisk relevante bivirkninger indberettet hos ≥1 % og <5 % af de patienter, som blev behandlet med ramucirumab plus docetaxel i REVEL, omfattede hyponatriæmi (4,8 % for ramucirumab plus docetaxel versus 2,4 % for placebo plus docetaxel), proteinuri (3,3 % for ramucirumab plus docetaxel versus 0,8 % placebo plus docetaxel) og gastrointestinal perforation (1 % for ramucirumab plus docetaxel versus 0,3 % placebo plus docetaxel).
Clinically relevant ADRs reported in ≥1% and <5% of the ramucirumab plus docetaxel-treated patients in REVEL were hyponatraemia (4.8% ramucirumab plus docetaxel versus 2.4% for placebo plus docetaxel), proteinuria (3.3% ramucirumab plus docetaxel versus 0.8% placebo plus docetaxel) and gastrointestinal perforation (1% ramucirumab plus docetaxel versus 0.3% placebo plus docetaxel).
Klinisk relevante bivirkninger, som blev rapporteret hos ≥ 1 % og < 5 % af patienter behandlet med ramucirumab plus paclitaxel i RAINBOW, omfattede gastrointestinal perforation (1,2 % for ramucirumab plus paclitaxel versus 0,3 % for placebo plus paclitaxel) og sepsis (3,1 % ramucirumab plus paclitaxel versus 1,8 % placebo plus paclitaxel).
Clinically relevant ADRs reported in ≥1% and <5% of the ramucirumab plus paclitaxel-treated patients in RAINBOW were gastrointestinal perforation (1.2% ramucirumab plus paclitaxel versus 0.3% for placebo plus paclitaxel) and sepsis (3.1% ramucirumab plus paclitaxel versus 1.8% placebo plus paclitaxel).
Klinisk relevante blødninger (Svær og CRNM),b n (%)
Clinically Relevant Bleeding (Major and CRNM)b, n (%)
Klinisk relevante eller alvorlige abnormaliteter ved rutinemæssige hæmatologiske eller biokemiske laboratorieværdier er vist i tabel 3.
Clinically relevant or severe abnormalities of routine haematological or biochemistry laboratory values are presented in Table 3.
Klinisk relevante interaktioner forventes med CYP3A4- og CYP2B6-substrater og, ud fra ekstrapolation, med UGT'er, CYP2C- og P-gp- substrater (se pkt.
Clinically relevant interactions are expected with CYP3A4 and CYP2B6 substrates and by extrapolation, UGTs, CYP2C and P-gp substrates (see section 4.5).
Klinisk relevante plasmaniveauer bestemmes primært af tiden, det tager plasmakoncentrationen af sufentanil at falde fra Cmax til 50 % af Cmax efter seponering (CST½), frem for den terminale halveringstid.
Clinically relevant plasma levels are largely determined by the time for the sufentanil plasma concentration to drop from Cmax to 50 % of Cmax after discontinuation of dosing (context sensitive half- time or CST½) rather than by the terminal half-life.
Klinisk relevante reduktioner i
White and non-White) were small.
Klinisk relevante ændringer i tenofovirs farmakokinetik blev ikke observeret hos patienter med let til moderat nedsat leverfunktion, og derfor er en dosisjustering af tenofoviralafenamid ikke nødvendig hos patienter med let til moderat nedsat leverfunktion.
Clinically relevant changes in tenofovir pharmacokinetics were not observed in patients with mild to moderate hepatic impairment, and no tenofovir alafenamide dose adjustment is required in patients with mild to moderate hepatic impairment.
Klinisk relevante ændringer i tenofovirs farmakokinetik hos patienter med nedsat leverfunktion blev ikke observeret hos patienter med let til moderat nedsat leverfunktion, og derfor er en dosisjustering af tenofoviralafenamid ikke nødvendig hos patienter med let til moderat nedsat leverfunktion.
Clinically relevant changes in tenofovir pharmacokinetics in patients with hepatic impairment were not observed in patients with mild to moderate hepatic impairment, and no tenofovir alafenamide dose adjustment is required in patients with mild to moderate hepatic impairment.
Klinisk remission
Clinical response at Week 30a
Klinisk remission hos patienter:
Clinical Remission in patients:
Klinisk remission i uge 30a
Clinical remission at week 30a
Klinisk remission i uge 30a
Clinical remission at Week 30a 13.1
Klinisk remission i uge 8 var 33,3 % (17/51) målt ved pæ diatrisk colitis ulcerosa aktivitets-indeks (PUCAI) scoren.
Clinical remission at week 8 was 33.3% (17/51) as measured by the Paediatric Ulcerative Colitis Activity Index (PUCAI) score.
Klinisk remission i uge 8a
Clinical remission at week 8a
Klinisk remission i uge 8a
Mucosal healing at week 8a
Klinisk remission, uge 10
Clinical remission, Week 10
Klinisk remission, uge 6
Clinical remission, Week 6
Klinisk remission§
Clinical remission§
Klinisk resistens hos patienter, der fik adefovirdipivoxil som monoterapi og i kombination med lamivudin: I flere kliniske studier (HBeAg-positive, HBeAg-negative, præ- og post- levertransplanterede patienter med lamivudin-resistent HBV og patienter med lamivudin-resistent HBV, der samtidig var inficeret med hiv) blev genotypeanalyser udført på HBV-isolater fra 379 ud af i alt 629 patienter, som var blevet behandlet med adefovirdipivoxil i 48 uger.
Clinical resistance in patients receiving adefovir dipivoxil as monotherapy and in combination with lamivudine: In several clinical studies (HBeAg positive, HBeAg negative, pre- and post-liver transplantation with lamivudine-resistant HBV and lamivudine-resistant HBV co-infected with HIV patients), genotypic analyses were conducted on HBV isolates from 379 of a total of 629 patients, treated with adefovir dipivoxil for 48 weeks.
Klinisk resistens hos voksne: Patienter i kliniske forsøg, der initialt blev behandlet med entecavir 0,5 mg (ikke tidligere behandlet med nukleosid) eller 1,0 mg (lamivudinrefraktære), og hvor PCR HBV-DNA er målt under behandling ved eller efter Uge 24, er monitorerede for resistens.
Clinical resistance in Adults: patients in clinical trials initially treated with entecavir 0.5 mg (nucleoside-naive) or 1.0 mg (lamivudine-refractory) and with an on-therapy PCR HBV DNA measurement at or after Week 24 were monitored for resistance.
Klinisk respons (100 point), uge 6
Clinical Response (100 point), week 6
Klinisk respons (100 point), uge 8
Clinical Response (100 point), week 8
Klinisk respons (CR- 100)
Clinical response (CR- 100)
Klinisk respons (regulering + N24CRS
Clinical response (Entrainment + N24CRS
Klinisk respons efter uge 16 i studierne ESTEEM 1 og ESTEEM 2 (FAS a LOCFb)
Clinical response at week 16 in studies ESTEEM 1 and ESTEEM 2 (FAS a, LOCFb)
Klinisk respons er fald fra baseline i Mayo score på > 3 point og > 30 % samt et fald i rektal blødning-subscore [RBS] på > 1 eller en absolut RBS på 0 eller 1;
Clinical response is decrease from baseline in Mayo score ≥ 3 points and ≥ 30% plus a decrease in the rectal bleeding subscore [RBS] ≥ 1 or an absolute RBS of 0 or 1;
Klinisk respons er fald fra baseline i Mayo score på > 3 point og > 30 % samt et fald i rektal blødning-subscore [RBS] på > 1 eller en absolut RBS på 0 eller 1;
Clinical response is decrease from baseline in Mayo score ≥3 points and ≥30% plus a decrease in the rectal bleeding subscore [RBS] ≥1 or an absolute RBS of 0 or 1;
Klinisk respons i uge 30a
Clinical response at week 30a
Klinisk respons i uge 8a
Clinical response at week 8a
Klinisk respons målt på varighed og tidspunkt af søvn-vågen tilstand
Clinical response in sleep-wake amount and timing measures
Klinisk respons ses normalt inden for 3-4 dage.
A clinical response is normally seen within 3-4 days.
Klinisk respons ved Non-24-Hour Sleep-Wake Disorder
Clinical Response in Non-24-Hour Sleep-Wake Disorder
Klinisk respons ved opfølgning (dag 12-14), efter analysepopulation
Clinical Response at Follow-up (day 12-14), by Analysis population
Klinisk respons5
Clinical Response5
Klinisk responsa
Fistula Response (%)a
Klinisk signifikans af dette
The clinical significance of
Klinisk signifikant aktiv blødning.
Clinically significant active bleeding.
klinisk signifikant nedsat leverfunktion samtidig eller planlagt indgift af en anden parenteral glykoprotein-(GP) IIb/IIIa-hæmmer.
clinically significant hepatic impairment concomitant or planned administration of another parenteral glycoprotein (GP) IIb/IIIa inhibitor
Klinisk signifikant respirationsdepression kan forekomme med fentanyl, og patienter skal observeres for disse symptomer.
Clinical significant respiratory depression may occur with fentanyl, and patients must be observed for these effects.
Klinisk signifikant vægtøgning (≥ 7 %) synes at forekomme hyppigst i den unge population sammenlignet med ældre med sammelignelig eksponering.
Clinically significant weight gain (≥ 7 %) appears to occur more frequently in the adolescent population compared to adults with comparable exposures.
Klinisk signifikante farmakokinetiske interaktioner mellem vismodegib og P-glykoprotein (P-gp)- hæmmere forventes ikke.
Clinically significant PK interactions between vismodegib and P-gp inhibitors are not expected.
klinisk signifikante.
clinically significant.
Klinisk sikkerhed og virkning
Clinical efficacy and safety
Klinisk SO 1
Clinical SO 1
klinisk status under eller efter perioden med samtidig
after the period of
Klinisk studie
Clinical Study
Klinisk studie CT-AMT-010-01
Clinical trial CT-AMT-010-01
Klinisk studie CT-AMT-011-02
Clinical trial CT-AMT-011-02
Klinisk studie hos patienter med ikke-transfusionsafhængige thalassæmi-syndromert
Clinical study in patients with non-transfusion-dependent thalassaemia syndromes
Klinisk studie hos patienter med tidligere ubehandlet CML i kronisk fase.
Clinical study in chronic phase previously untreated CML
Klinisk studie med forsøgspersoner med fremskreden kronisk nyresygdom med kronisk hepatitis C- infektion af genotype 1
Clinical study in subjects with advanced chronic kidney disease with genotype 1 CHC infection
Klinisk studie med patienter med imatinib-resistent eller -intolerant CML i kronisk fase, accelereret fase eller blastfase
Clinical study in imatinib-resistant or intolerant CML in chronic phase, accelerated phase, and blast phase.
Klinisk studiedesign: Den kliniske effekt af BRINAVESS i behandlingen af patienter med atrieflimren er blevet vurderet i tre randomiserede, dobbeltblindede, placekontrollerede undersøgelser (ACT I, ACT II og ACT III) og i et aktivt komparatorstudie versus intravenøs amiodaron (AVRO).
Clinical Trial Design: The clinical effect of BRINAVESS in the treatment of patients with atrial fibrillation has been evaluated in three, randomised, double-blind, placebo-controlled studies, (ACT I, ACT II and ACT III) and in an active comparator trial versus intravenous amiodarone (AVRO).
Klinisk studier hos patienter med kronisk hepatitis C genotype 4-infektion
Clinical trials in subjects with genotype 4 chronic hepatitis C
Klinisk succes
Clinical Success
Klinisk succesrate 4 uger efter endt behandling
Clinical success rate 4 weeks after end of treatment
Klinisk succesrate på dag 14
Clinical success rate at Day 14
Klinisk succesrate ved opfølgning af SIOW-patienter med S. aureus
Clinical Success Rates at Follow up for SIOW patients with S. aureus
Klinisk typiske, ikke-hyperkeratotiske, ikke-hypertrofiske aktiniske keratoser (AK´er) i ansigt eller hovedbund hos raske voksne patienter med normal immunstatus, når størrelsen af læsionerne eller antallet begrænser effekt og/eller mulig anvendelse af kryoterapi, og andre lokale behandlingsalternativer er kontraindicerede eller mindre velegnede.
Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AKs) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.
Klinisk ustabile patienter med akut promyelocyt leukæmi (APL) er specielt udsatte og vil kræve hyppigere monitorering af elektrolyt- og glykæmiske niveauer samt hyppigere hæmatologiske, hepatiske, renale og koagulationsparameteranalyser.
Clinically unstable APL patients are especially at risk and will require more frequent monitoring of electrolyte and glycaemia levels as well as more frequent haematologic, hepatic, renal and coagulation parameter tests.